Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs Nutrien Ltd (NTR) Price & Performance

Moderna, Inc.Trade
Nutrien LtdTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Nutrien Ltd — how do they compare? Moderna, Inc. trades at $63.65 (market cap $24.18B), while Nutrien Ltd trades at $66.6 (market cap $32.05B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays a 3.27% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

MRNANTR
Market Cap
$24.18B$32.05B
Sector
HealthBasic Materials
52-Week High
$81.80$83.94
52-Week Low
$22.36$53.64
Enterprise Value
$20.33B$43.86B
Dividend Yield
3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Nutrien Ltd

Nutrien (NTR) trades at $66.85, up 0.81% today, with a bearish technical signal despite neutral oscillators. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, driven by higher potash prices. The company maintains a stable dividend of $0.55 per share and shows improving net income margins, though cash flow trends have weakened. Analyst consensus is bullish with a $76.17 price target, highlighting structural advantages in nitrogen assets.

The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and volatile earnings pose risks. Key opportunities include exposure to agricultural cycles and cost advantages; risks involve input cost pressures and execution challenges in a competitive fertilizer market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About Nutrien Ltd

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

Read more on NTR